Squarepoint Ops LLC Takes $147,000 Position in BioDelivery Sciences International, Inc. (BDSI)

Squarepoint Ops LLC bought a new position in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 39,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $147,000. Squarepoint Ops LLC owned 0.06% of BioDelivery Sciences International as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BDSI. Point72 Asset Management L.P. boosted its position in BioDelivery Sciences International by 150.0% during the third quarter. Point72 Asset Management L.P. now owns 1,500,000 shares of the specialty pharmaceutical company’s stock valued at $4,200,000 after purchasing an additional 900,000 shares during the last quarter. Barclays PLC boosted its position in BioDelivery Sciences International by 942.8% during the fourth quarter. Barclays PLC now owns 328,039 shares of the specialty pharmaceutical company’s stock valued at $1,214,000 after purchasing an additional 296,582 shares during the last quarter. Wells Fargo & Company MN boosted its position in BioDelivery Sciences International by 121.7% during the third quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock valued at $331,000 after purchasing an additional 64,803 shares during the last quarter. Knott David M boosted its position in BioDelivery Sciences International by 33.8% during the fourth quarter. Knott David M now owns 500,300 shares of the specialty pharmaceutical company’s stock valued at $1,851,000 after purchasing an additional 126,300 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in BioDelivery Sciences International during the fourth quarter valued at $615,000. 57.09% of the stock is owned by institutional investors and hedge funds.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 23,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $5.07, for a total value of $116,610.00. Following the completion of the sale, the director now owns 544,187 shares of the company’s stock, valued at $2,759,028.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $5.00, for a total value of $10,000,000.00. The disclosure for this sale can be found here. Insiders sold 2,048,050 shares of company stock valued at $10,241,990 in the last ninety days. Insiders own 13.26% of the company’s stock.

A number of research firms recently issued reports on BDSI. Cantor Fitzgerald reissued a “buy” rating and set a $8.00 price objective on shares of BioDelivery Sciences International in a research report on Tuesday, April 16th. BidaskClub raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Friday, January 11th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of BioDelivery Sciences International in a research report on Friday, March 15th. Finally, Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $5.79.

BDSI opened at $4.65 on Friday. BioDelivery Sciences International, Inc. has a 1 year low of $1.70 and a 1 year high of $5.37. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). BioDelivery Sciences International had a negative return on equity of 79.59% and a negative net margin of 60.87%. The company had revenue of $18.03 million during the quarter, compared to analysts’ expectations of $16.15 million. On average, analysts expect that BioDelivery Sciences International, Inc. will post -0.24 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Squarepoint Ops LLC Takes $147,000 Position in BioDelivery Sciences International, Inc. (BDSI)” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/squarepoint-ops-llc-takes-147000-position-in-biodelivery-sciences-international-inc-bdsi.html.

BioDelivery Sciences International Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: Balanced Fund

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.